Daniel McCormick Raleigh, NC

Daniel McCormick is a formidable figure in the global commercial domain, showcasing expertise in sales, marketing leadership, operations, strategy, and planning. His extensive experience, spanning over 25 years in biotechnology, pharmaceuticals, diagnostics, and medical devices, has solidified his reputation for excellence in sales and marketing. His tenure as a Marine officer has instilled in him a strong sense of purpose and accountability, traits that are highly esteemed by his peers. He is celebrated for his people-centric approach and unwavering commitment to upholding high responsibility standards. His visionary leadership style and remarkable ability to foster productivity have earned him numerous accolades and recognition as a true innovator in the business landscape. Away from the rigors of his professional life, he is a devoted husband and a father to four children. He cherishes moments spent with his family and indulges in basketball, scuba diving, and exploring new cultures through international travel. These interests reflect his adventurous spirit and his deep commitment to family.

In his current professional chapter, he is the principal of Zensights, a biotech and pharmaceutical consulting firm based in Scottsdale, Arizona. Since September 2022, he has forged agile and innovative partnerships, connecting biopharmaceutical companies with top-tier industry partners. Under his leadership, Zensights fosters long-lasting client relationships, blending deep industry knowledge with fresh perspectives to achieve cost-effective solutions. Additionally, he holds the position of president at Generis Global Solutions, a specialized management consulting firm located in Raleigh, North Carolina. Since 2018, he has guided growth-oriented companies in the life sciences sector toward operational excellence, efficiency, and global revenue growth. Generis Global Solutions is committed to creating innovative commercial and medical affairs models, focusing on impactful results and optimizing return on investment.